Abstract
Background TB latent infection reflected as TB prevalence might give heterogeneous immunity for infection in mechanism like what happen in BCG This study the first to our knowledge, addressing TB prevalence influence and possibly an important predictor for Covid-19 mortality and its findings may help to satisfy world inquiries about diversities dilemma. This study also will address disparities raised before about variances in mortalities among countries with same BCG protocols.
Methods This study was set to look out for impact of TB prevalence on Covid-19 mortality on the context of countries vaccination status. Countries were divided into five groups according to BCG status. Covid-19 deaths are tested against TB prevalence through using (Non Linear Regression Modules) of predicted shapes behavior for each group.
Results Slopes values have highly significant influences between TB prevalence and Covid-19 deaths for overall studied group, and among countries currently given 1 BGG (2 groups) and ones with previous history of vaccinations, being significant in currently given more than 1 BCG and in countries without vaccination. There are meaningful nonlinear regression shapes which are logarithmic in whole countries and in countries with current just 1 vaccine setting. It is inverse in other 2 groups currently given vaccine. It is power and cubic in countries never given and with previously given vaccines respectively. All groups and whole sample shows either perfect or extremely perfect R-square (Determination Coefficient) values with significant in at least at P-values<0.05. Study denotes possibility of factor/s other than BCG prevalence (i.e. The intercept) were operating in different ranges within groups.
Conclusion High TB prevalence together with continuing BCG programs decrease COVID-19 Mortalities in different countries.
Strengths and limitations of this study
To our knowledge, this study will be the first addressing TB Prevalence influence and possibly an important predictor for Covid-19 mortality and its findings may help to satisfy world inquiries about diversities dilemma.
This study also will address disparities raised before about variances in mortalities among countries with same BCG protocols.
Potential confounding factors still exist.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
no funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
I used public data available for public
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data referred to in the manuscript are available on requist
